Rationally Engineered Proteins or Antibodies with Absent or Reduced Immunogenicity

E-ISSN： 1875-533x|9|24|2191-2199

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.9, Iss.24, 2002-12, pp. : 2191-2199

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Structure-Immunogenicity Relationships of Therapeutic Proteins

By Hermeling Suzanne Crommelin Daan J. A. Schellekens Huub Jiskoot Wim

Pharmaceutical Research, Vol. 21, Iss. 6, 2004-06 ,pp. : 897-903

Springer Publishing Company

Access to resources Recommend Favorite

Immunogenicity Issues in the Development of Therapeutic Proteins

By Swanson Steven J.

International Journal of Pharmaceutical Medicine, Vol. 21, Iss. 3, 2007-01 ,pp. : 207-216

Adis International

Access to resources Recommend Favorite

Immunogenicity Assessment of Therapeutic Proteins and Peptides

Current Pharmaceutical Biotechnology, Vol. 10, Iss. 4, 2009-06 ,pp. : 352-358

Bentham Science Publishers

Access to resources Recommend Favorite

Can Selective Ligands for Glutamate Binding Proteins be Rationally Designed?

Current Topics in Medicinal Chemistry, Vol. 6, Iss. 8, 2006-04 ,pp. : 823-847

Bentham Science Publishers

Access to resources Recommend Favorite

Fluorescent ligands, antibodies, and proteins for the study of receptors

By Daly C.J. McGrath J.C.

Pharmacology and Therapeutics, Vol. 100, Iss. 2, 2003-11 ,pp. : 101-118

Elsevier

Access to resources Recommend Favorite